The first subjects have been successfully dosed with AX-202 at The Medicines Evaluation Unit in Manchester UK In this phase 1 trial, Arxx Therapeutic’s monoclonal antibody AX-202 is being tested in healthy volunteers and patients with psoriasis, leading into Arxx’s program in systemic sclerosis Oslo, Norway, 8 May 2023 – Arxx Therapeutics, a Norwegian-Danish […]